Lawsone develops complete, licensable formulation dossiers for marketed drugs: master formula, manufacturing procedure, specifications, and equivalence evidence, all validated by simulation. You license the dossier; you skip the guesswork.
20 mg immediate-release tablet. Candidate master formula plus granulation process and specifications on standard equipment; no special infrastructure required. Simulation-validated equivalence; documented failure-mode analysis included.
145 mg nanocrystal tablet requiring wet bead-milling. Full quantitative recipe confirmed across three regulatory regions; mill parameters, stabilizer system, and discriminating dissolution design included.
Every figure in a Lawsone dossier is tagged to its evidence class. You always know what is documented and what is inference, so your regulatory and patent teams can diligence the file line by line instead of trusting a black box.
We never claim the innovator's confidential manufacturing record. What we deliver is a defensible point inside the equivalence region: a candidate formula and process whose every number carries a citation, a rationale, or a flagged hypothesis to test in your first batch.
Non-confidential overview: asset class, evidence depth, licensing terms.
Mutual NDA, then compound identity plus the stage-1 evidence pack.
Your team reviews the evidence map, dissolution overlays, robustness report.
Territorial license: upfront, milestones, profit share. Formula under signature.